AtriCure, Inc. (ATRC)
| Market Cap | 2.86B +79.6% |
| Revenue (ttm) | 589.80M +13.8% |
| Net Income | 14.88M |
| EPS | 0.31 |
| Shares Out | 50.92M |
| PE Ratio | 183.01 |
| Forward PE | 166.08 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 211,304 |
| Open | 56.42 |
| Previous Close | 56.26 |
| Day's Range | 56.03 - 57.29 |
| 52-Week Range | 25.36 - 66.02 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | 64.89 (+15.46%) |
| Earnings Date | Nov 3, 2026 |
About ATRC
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation Sys... [Read more]
Financial Performance
In 2025, AtriCure's revenue was $534.53 million, an increase of 14.88% compared to the previous year's $465.31 million. Losses were -$11.45 million, -74.39% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ATRC stock is "Buy." The 12-month stock price target is $64.89, which is an increase of 15.46% from the latest price.
News
AtriCure Transcript: UBS Global Healthcare Conference
EnCompass is driving cardiac ablation adoption, while pain management continues to broaden across surgical procedures. Management sees long market runways, plans sales-territory investments in 2027 ahead of an anticipated 2028 PMA, and targets long-term adjusted EBITDA margins above 20%.
AtriCure price target raised to $70 from $63 at BTIG
BTIG analyst Marie Thibault raised the firm’s price target on AtriCure (ATRC) to $70 from $63 and keeps a Buy rating on the shares. The firm cites the company’s better-than-expected…
AtriCure price target raised to $62 from $36 at JPMorgan
JPMorgan analyst Lilia-Celine Lozada raised the firm’s price target on AtriCure (ATRC) to $62 from $36 and keeps a Neutral rating on the shares.
AtriCure price target raised to $70 from $60 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on AtriCure (ATRC) to $70 from $60 and keeps an Overweight rating on the shares. The firm notes Atricure reported…
AtriCure price target raised to $67 from $55 at Canaccord
Canaccord raised the firm’s price target on AtriCure (ATRC) to $67 from $55 and keeps a Buy rating on the shares. The firm updated its model as AtriCure delivered a…
AtriCure price target raised to $70 from $65 at Stifel
Stifel raised the firm’s price target on AtriCure (ATRC) to $70 from $65 and keeps a Buy rating on the shares.
AtriCure Earnings Call Transcript: Q3 2026
Q3 revenue grew 15% and adjusted EBITDA rose 50.6%, with strength in U.S. franchises. FY2026 adjusted EBITDA guidance increased to $91M-$94M, while hybrid ablation and international markets remain headwinds.
AtriCure Earnings release: Q3 2026
AtriCure released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
AtriCure Quarterly report: Q3 2026
AtriCure has published its Q3 2026 quarterly earnings report on November 3, 2026.
AtriCure Slides: Q3 2026
AtriCure has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
AtriCure reports Q3 EPS 18c, consensus 1c
Reports Q3 revenue $154.5M, consensus $151.2M. “Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution,” said Michael Carrel, President and Chie...
AtriCure sees FY26 EPS 4c-46c , consensus 28c
Sees FY26 revenue $606M-$610M, consensus $606.3M
AtriCure Reports Third Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
AtriCure to Participate at Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure price target raised to $68 from $52 at Citizens
Citizens raised the firm’s price target on AtriCure (ATRC) to $68 from $52 and keeps an Outperform rating on the shares. AtriCure shares have surged on growing recognition of its…
AtriCure to Announce Third Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure price target raised to $63 from $55 at BTIG
BTIG raised the firm’s price target on AtriCure (ATRC) to $63 from $55 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
AtriCure downgraded to Hold from Buy at Freedom Capital
Freedom Capital analyst Keith Hinton downgraded AtriCure (ATRC) to Hold from Buy with a price target of $57, up from $43. The firm expects BoX-NoAF POAF data that should be…
AtriCure Transcript: Wells Fargo 21st Annual Healthcare Conference
Management outlined progress ahead of long-term targets, with strong growth in pain management and clinical trials advancing faster than planned. New product launches and ongoing investments in innovation are expected to sustain momentum, while market expansion and quality initiatives provide additional growth catalysts.
AtriCure price target raised to $60 from $50 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on AtriCure (ATRC) to $60 from $50 and keeps an Overweight rating on the shares. Earlier this year, STS introduced…
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...
AtriCure price target raised to $55 from $45 at BTIG
BTIG raised the firm’s price target on AtriCure (ATRC) to $55 from $45 and keeps a Buy rating on the shares. The company’s new STS Quality Metric could increase use…
AtriCure Transcript: Canaccord Genuity's 46th Annual Growth Conference
Management highlighted strong growth, profitability, and leadership in AFib and pain management, with major clinical trials set to expand market opportunities. Financial performance is robust, driven by innovation and operational leverage, while competitive differentiation is maintained through proprietary technology and clinical evidence. Free cash flow will support organic growth and R&D.
AtriCure price target lowered to $50 from $55 at UBS
UBS lowered the firm’s price target on AtriCure (ATRC) to $50 from $55 and keeps a Buy rating on the shares. Business growth excluding MIS is expected to support sustainable…
AtriCure Earnings Call Transcript: Q2 2026
Q2 2026 saw 12.8% revenue growth, strong profitability, and margin expansion, led by pain management and appendage management. Strategic clinical trials and new product launches support future growth, while guidance for 2026 was raised for both revenue and adjusted EBITDA.